All In Biotech

Drug Trial Radar · NCT05813496

Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt

A Multicenter, Interventional, Two-arm, Parallel-group, Randomized, Double-blinded, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy of Alpha-Lipoic Acid in the Treatment of Symptomatic Diabetic Polyneuropathy in Egypt

Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 430 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

430

Actual

Start

Oct 26, 2022

Primary completion

Aug 3, 2024

Study completion Dec 11, 2024

Sponsor

Lead sponsor
Eva PharmaIndustry
Sponsor type
Industry
Collaborators
MARC-CRO
First posted
Apr 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to find out whether ALA is effective and safe for treating Egyptian diabetic patients with symptomatic polyneuropathy. The ADA stated that despite the exploration of several pharmacological therapies for DPN management, substantial evidence on medicines that modify the natural history of DPN is still absent. This is a multicenter, interventional, two-arm, parallel-group, randomized, double-blinded, placebo-controlled, phase IV trial. Patients will be administered either one tablet of placebo or one tablet containing 600 mg of ALA twice a day for 24 weeks, depending on the randomization process.

Conditions

  • Polyneuropathy, Diabetic

Interventions

  • Alpha-Lipoic Acid (ALA)Drug

    Oral tablet

  • PlaceboDrug

    Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the relative change in NCS parameters between the study armsTime frame: After four weeks of treatment

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Mansoura University Hospital

    Al Mansurah, Egypt

  • Alexandria University

    Alexandria, Bab Sharqi, Egypt

  • Beni Suef University Hospital

    Banī Suwayf, Beni Suweif Governorate, Egypt

  • Ain-Shams University Hospital

    Cairo, Heliopolis, Egypt

  • Menoufia University Hospital

    Shibīn al Kawm, Shebin El Kom, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.